UNICREDIT BANK/CALL/ASTRAZENECA/12000/0.1/18.06.25 | Market Closed - Börse Stuttgart 14:44:09 2024-06-20 EDT | ||
| 1.87 EUR | 0.00% |
|
| Current month | +6.25% | ||
| 1 month | +14.72% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-06-20 | 1.87 | 0.00% |
| 24-06-19 | 1.87 | -2.09% |
| 24-06-18 | 1.91 | -2.55% |
| 24-06-17 | 1.96 | -3.45% |
| 24-06-14 | 2.03 | +6.28% |
Delayed Quote Börse Stuttgart
Last update June 20, 2024 at 02:44 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HD1H8A |
| ISIN | DE000HD1H8A8 |
| Date issued | 2023-12-28 |
| Strike | 12,000 p |
| Maturity | 2025-06-18 (363 Days) |
| Parity | 10 : 1 |
| Emission price | 0.86 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.1 € |
|---|---|
| Lowest since issue | 0.35 € |
| Spread | 0.04 € |
| Spread % | 2.07% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.2
USD
Average target price
174.4
USD
Spread / Average Target
+11.00%
- Stock Market
- Warrants
- Warrant
